July #103 : C No Evil? - by Bob Lederer

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
Newsletters
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join
Username:
Password:

Back to home » Archives » POZ Magazine issues




Table of Contents

Lost In Paradise

Kiss & Tell

Our Infectors, Ourselves

Velvet Gloves

A Pathway to Peace

His Diff'rent World

Earthwatch

Fear Factor

African Idols

Tribute: Keith Cylar

Burning Rubber

War of the Worlds

Oprah on the DL

C No Evil?

When Nature Calls

Briefs

Liver It Up

Inner Guinea Pig

Cancer Rising

Quick Study: Dementia

Senior Class

Women('s) Count(s)

Fit to Print

The Acting Bug

Editor's Letter

Mailbox

The Art of Healing



Most Popular Lessons

The HIV Life Cycle

Shingles

Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV


email print

July 2004

C No Evil?

by Bob Lederer

Coinfection bedevils at least one-third of HIVers. Bob Lederer dissects the tricks of treatment

Tale of Two Viruses


Studies give HIVers coinfected with genotype 1 hepatitis C virus (HCV) only a 14 to 29 percent chance of responding to HCV treatment. But someone forgot to tell Bill Ballard. Having finished the standard treatment—pegylated interferon plus ribavirin—Ballard seems to have quashed HCV. The side effects sucked, but his triumph should inspire thousands of other coinfectees. Right on time, too: Liver disease (cirrhosis, or severe scarring, and cancer), which can result from HCV, has become a top cause of HIVer death.

Ballard, of Yonkers, New York, had kicked heroin and was working as an emergency medical technician when he was diagnosed with both viruses in 1994—“the gift that keeps on giving,” Ballard laughs. He began an HIV regimen—AZT (Retrovir) and delavirdine (Rescriptor), later adding 3TC (Epivir) and abacavir (Ziagen)—keeping CD4s above 200, viral load low to undetectable and side effects minimal.

But for years, his medical team, led by nurse practitioner Pat Ames, saw little point in treating his HCV because the available meds were ineffective. Besides, periodic measures of Ballard’s liver enzymes didn’t show inflammation.

Then, in 2001, shortly after the FDA improved treatment by approving pegylated interferon, which stays in your body longer than the non-peg kind, a sonogram of Ballard’s liver revealed fatty deposits. A biopsy—the “gold standard” for measuring liver damage, analyzing a piece of liver extracted with a needle—found stage-1 fibrosis, or mild scarring (stage 4, the worst, means cirrhosis). Ballard says, “I wanted treatment before anything else happened to my liver.”

Start or Stall?

Deciding if and when to take hep C meds can be tricky. Most specialists agree that HIVers with fewer than 200 CD4 cells should first up the count with HAART and that CD4s should hold steady before HCV treatment begins. They also agree that those with the more treatable genotypes 2 and 3 should start after a stage-1 biopsy. But for genotype 1, “many experts recommend deferring treatment until stages 3 or 4, repeating a biopsy in two to three years,” says Brad Hare, MD, a coinfection pro at San Francisco General Hospital. You could start C therapy sooner, though, he advises, “if you’re having liver toxicity from HIV medications” and need liver repair in order to handle an HIV combo.

If a biopsy mandates treatment, brace yourself. “You’ll be starting a year’s worth of therapy with lots of side effects,” Hare says. “You’ll need personal support, stable housing and mental-health care.”

The manufacturers’ patient assistance programs helped Ballard pay for the combo (about $20,000). The paperwork took nearly a year. And because he has a history of depression—interferon can cause or worsen it—he had psychiatric tests and was prescribed antidepressants before starting treatment.

Finally, in October 2002, Ballard started weekly pegylated-interferon injections plus twice-daily ribavirin pills. Three months later, his HCV viral load had fallen from 900,000 to undetectable. “My nurse practitioner didn’t believe the results,” he says. The unbelievable has held up on four more tests. He ended the treatment on time, a year later. “If my next HCV test is still undetectable, they’ll consider the virus eradicated,” Ballard says.

“He’s a strong-willed guy,” Ames says. “He kept his appointments; he wasn’t drinking or using drugs during treatment.” Ballard says, “I adhere well, with extremely good support—from my 16-year-old twin girls, my mother and my HIV program.”

That Flu From Hell

He needed it. “After my first shot I had a 104-degree fever,” Ballard recalls, with “shakes so bad that my daughters had to help me into the bathroom. The inteferon took away my appetite, and I lost 26 pounds. I had complete body pain.” But after three weeks, “the aches and pains went away,” he says.

He dumped the antidepressants after a month and managed fine without them. But five months after ending treatment, his appetite is still AWOL, leaving his belly sore.

Ribavirin can produce anemia, so Ballard switched his anemia-prone AZT to d4T during hep C therapy, and interferon can cause thrombocytopenia (low platelets) and neutropenia (low white blood cells). The upshot: HCV combo therapy can result in fatigue and a temporary drop in an HIVer’s CD4 count. Add near-universal nausea and post-injection “flu from hell,” and “some people in my program said, ‘Hell, no, I’m not doing this,’” Ballard says.

Hang tough by “educat[ing] yourself about the tests, treatments and track records” before racing toward therapy, Ames advises. Doctors often disagree on whether patients with dim prospects of success should brave the misery. If at three months viral load hasn’t fallen by at least a factor of 100, most docs would recommend bailing.

Others advise caution before starting: “HCV is often slow-progressing,” says Daniel Raymond, a treatment specialist with the Harm Reduction Coalition in New York City. “Some people will live their whole life without ever having to treat. If you can avoid these toxic drugs, do it. Understanding if there really is [significant] liver disease is the first step.”

For Ballard, that first step is so yesterday. “I’m more worried about getting hit by a bus than about dying from either HIV or HCV,” he says. “I’m kicking both of these in the butt.”


When Nature Calls

If standard hep C treatment—ribavirin (Rebetol, Copegus or the generic Ribasphere, approved in April) taken in combination with pegylated interferon (Pegasys or Peg-Intron)—doesn’t liver up to your expectations, go natural, but only under professional supervision. These have shown promise in studies (also see “Liver It Up,”):

Chinese herbs—Licensed practitioners can dispense 10-herb Hepatoplex 1 (call 510.639.0280). But high doses of one ingredient, licorice, can raise blood pressure and drop testosterone (already low in some HIVers).

Western herbs—Silymarin (milk thistle) may reduce HCV liver inflammation. (A coinfectee study began in New York City in June; 718.622.0212.) Check with Doc before wetting your whistle with thistle if you’re on HCV meds.

Supplements—Antioxidants (especially vitamins C and E, zinc, selenium and alpha-lipoic acid) can limit liver damage. The amino acid glutamine can help restore your body’s natural glutathione, which the liver taps when breaking down nutrients, drugs and toxins.




[Go to top]

Facebook Twitter Google+ MySpace YouTube Tumblr Flickr Instagram
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar
POZ on Twitter

Ask POZ Pharmacist

Talk to Us
Poll
Are you buying holiday gifts that raise HIV/AIDS awareness?
Yes
No

Survey
Smoke Signals

more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.